Meta-analysis of statin combined with trimetazidine on the regulation of inflammatory factors in coronary atherosclerotic heart disease and improvement of ventricular remodeling

Objective:To systematically evaluate the effects of statins combined with trimetazidine on the regulation of inflammatory factors and the improvement of ventricular remodeling in coronary atherosclerotic heart disease based on the inflammasomes/immune damage response theory.Methods:Using computer to search for EMbase,The Cochrane Library,Web of Science,MEDLINE,PubMed,WanFang Data,CNKI,China Biomedical Document Service System(CBM),VIP database(VIP),9 databases in total.The search time limit is from the inception of the databases to June 7,2021.All reference documents included in the study were manually searched.According to the Cochrane systematic review method,the information on atorvastatin combined with trimetazidine and conventional treatment(antiplatelet,control blood pressure,diuresis,coronary artery dilation and other expectant treatments)contrast the use of trimetazidine or stains combined with expectant treatment of coronary atherosclerotic heart disease patients in Chinese and English randomized controlled trials(RCT),and conduct the extraction and quality evaluation of the included literature data,using RevMan5.4 software for Meta analysis.Outcome indicators include inflammatory factors:C-reactive protein(CRP),IL-6(interleukin 6),tumor necrosis factor(TNF-α),and ventricular remodeling related outcome indicators:left ventricular end diastolic diameter(LVEDD),left Ventricular end systolic diameter(LVESD).Results:12 randomized controlled trials were included,a total of 1120 patients with coronary heart disease.Meta-analysis results:(1)inflammatory factors:the statin combined with trimetazidine group can significantly reduce the CRP,IL-6,TNF-α’s expression degree in the blood of patients with coronary heart disease compared with the control group(only statins or trimetazidine).CRP[n=770,SMD=-2.70,95%CI(-2.55,-1.40),P<-0.00001],TNF-α[n=678,SMD=-2.25,95%CI(-3.39,-1.12),P<-0.0001],IL-6[n=770,SMD=-2.10,95%CI(-3.10,-1.10),P<0.00001].(2)Ventricular remodeling:Compared with the control group(using statins or trimetazidine alone),the statin combined with trimetazidine group can significantly reduce the left ventricular end-systolic diameter of patients with coronary heart disease before treatment[n=626,SMD=-1.55,95%CI(-2.10,-0.99),P<-0.00001]and leftVentricular end diastolic diameter[n=626,SMD=-1.18,95%CI(-1.56,-0.80),P<-0.00001].Conclusion:Compared with the control group,statins combined with trimetazidine can significantly reduce the level of inflammatory factors based on the inflammasomes/immune injury response theory,and improve the ventricular remodeling in patients with coronary heart disease.

Real-time Three-dimensional Echocardiographic Assessment of Left Ventricular Remodeling Index in Patients with Hypertensive Heart Disease and Coronary Artery Disease

Left ventricular remodeling index （LVRI） was assessed in patients with hypertensive heart disease （HHD） and coronary artery disease （CAD） by real-time three-dimensional echocardiography （RT3DE）. RT3DE data of 18 patients with HHD, 20 patients with CAD and 22 normal controis （NC） were acquired. Left ventricular end-diastolic volume （EDV） and left ventricular end-diastolic epicardial volume （EDVepi） were detected by RT3DE and two-dimensional echocardiography Simpson biplane method （2DE）. LVRI （left ventricular mass/EDV） was calculated and compared. The results showed that LVRI measurements detected by RT3DE and 2DE showed significant differences inter-groups （P〈0.01）. There was no significant difference in NC group （P〉0.05）, but significant difference in HHD and CAD intra-group （P〈0.05）. There was good positive correlations between LVRI detected by RT3DE and 2DE in NC and HHD groups （t=0.69, P〈0.01; r=0.68, P〈0.01）, but no significant correlation in CAD group （r=0.30, P〉0.05）. It was concluded that LVRI derived from RT3DE as a new index for evaluating left ventricular remodeling can provide more superiority to LVRI derived from 2DE.

Effects of telmisartan combined with nifedipine controlled release tablet on inflammatory factors, vascular endothelial function and left ventricular function in patients with coronary heart disease with mild to moderate hypertension

Objective: To investigate the effect of telmisartan combined with Nifedipine Controlled Release Tablet on inflammatory factors, vascular endothelial function and left ventricular function in patients with coronary heart disease with mild to moderate hypertension. Methods:A total of 92 cases of patients with coronary heart disease with mild to moderate hypertension were selected as the object of observation, according to the random data table, they were divided into the control group (n=46) and observation group (n=46), and patients in the control group were treated with Nifedipine Controlled Release Table therapy, on this basis, the observation group patients were given telmisartan treatment, two groups were treated for 6 months. The levels of the blood pressure, inflammatory factors, vascular endothelial function and left ventricular function compared between the two groups before and after treatment. Results: There were no significant differences in the levels of SBP, DBP, hs-CRP, TNF-α, NO, ET-1, LVEF, LVEDD and LVESD in the two groups before treatment. After treatment, two groups of SBP, DBP, hs-CRP, TNF-α, ET-1, LVEDD and LVESD levels were significantly lower than those in the same group before treatment, and after treatment, the levels of SBP, DBP, hs-CRP, TNF-α, ET-1 and LVESD in the observation group were significantly lower than those in the control group, while there were no significant difference in the level of LVEDD between the two groups after treatment;Compared with level in the group before treatment, the levels of NO and LVEF in the two groups were significantly increased, and the observation group [(82.13±19.01) μmol/L, (52.83±7.45)%] was significantly higher than the control group ((67.37±13.08) μmol/L, (49.47±6.96)%)Conclusion: Telmisartan combined with Nifedipine Controlled Release Table in treating coronary heart disease with mild to moderate hypertension, can effectively control blood pressure, reduce the inflammatory stress, improve vascular endothelial function and left ventricular function of patients, has an important clinical value.

Ultrasonographic assessment of cardiac function and disease severity in coronary heart disease

BACKGROUND Coronary heart disease(CHD)causes many adverse cardiovascular events and poses a threat to the patient’s health and quality of life.AIM To evaluate ultrasonography for evaluation of cardiac function and lesion degree in patients with CHD.METHODS A total of 106 patients with CHD(study group)and 106 healthy individuals(control group)in our hospital from March 2019 to September 2020 were selected for this study.All subjects were examined by ultrasound,and the mitral orifice’s early-to-late diastolic blood flow velocity ratio(E/A),left ventricular end-diastolic volume(LVDd),and left atrial diameter(LAD)were measured.Values were compared between the study group and healthy group,and the correlation between the ultrasonic parameters of patients with different cardiac function grades and the degree of CHD were assessed.In addition,the ultrasonic parameters of patients with different prognoses were compared after a follow-up for 6 mo.RESULTS E/A(1.46±0.34)of the study group was smaller than that of the control group(1.88±0.44),while LVDd(58.24±5.05 mm)and LAD(43.31±4.38 mm)were larger(48.15±3.93 and 34.94±2.81,respectively;P<0.05).E/A for patients with grade III disease(1.41±0.43)was smaller and their LVDd(60.04±4.21 mm)and LA(44.16±2.79 mm)were larger than those in patients with grade II disease(1.71±0.48,52.18±3.67 mm,and 39.68±2.37,respectively;P<0.05).Patients with grade IV disease had smaller E/A(1.08±0.39)and larger LVDd(66.81±5.39 mm)and LAD(48.81±3.95 mm)than patients with grade II and III disease(P<0.05).In patients with moderate disease,E/A(1.44±0.41)was smaller and LVDd(59.95±4.14 mm)and LAD(45.15±2.97 mm)were larger than in patients with mild disease(1.69±0.50,51.97±3.88 and 38.81±2.56 mm,respectively;P<0.05).In patients with severe disease,E/A(1.13±0.36)was smaller and LVDd(67.70±6.11 mm)and LAD(49.09±4.05 mm)were larger than in patients with moderate disease(P<0.05).E/A was negatively correlated with cardiac function classi-fication and disease severity,while LVDd and LAD were positively correlated with cardiac function classification and disease severity(P<0.05).E/A(1.83±0.51)for patients with good prognosis was higher than that for those with poor prognosis(1.39±0.32),while LVDd(49.60±4.39 mm)and LAD(36.13±3.05 mm)were lower(P<0.05).CONCLUSION The ultrasonic parameters of patients with CHD are abnormal,and differ significantly in patients with different cardiac function grades,lesion degree,and prognosis.

Effect of Trimetazidine on Diabetic Patients with Coronary Heart Diseases: A Meta-Analysis of Randomized, Controlled Trials

Objective To explore the therapeutic effects of trimetazidine(TMZ)on diabetic patients with coronary heart diseases.Methods We conducted a comprehensive electronic search of PubMed,EMBASE,and Cochrane databases between the inception dates of databases and May 2019(last search conducted on 30 May 2019)to identify randomized controlled trials.The evaluation method recommended by Cochrane Collaboration for bias risk assessment was employed for quality assessment.Random or fixed models were used to investigate pooled mean differences in left ventricular function,serum glucose metabolism,serum lipid profile,myocardial ischemia episodes and exercise tolerance with effect size indicated by the 95%confidence interval(CI).Results Additional TMZ treatment contributed to considerable improvement of left ventricular ejection fraction(WMD=4.39,95%CI:3.83,4.95,P<0.00001),left ventricular end diastolic diameter(WMD=-3.17,95%CI:-4.90,-1.44,P=0.0003)and left ventricular end systolic diameter(WMD=-4.69,95%CI:-8.66,-0.72,P=0.02).TMZ administration also significantly decreased fasting blood glucose(SMD=-0.43,95%CI:-0.70,-0.17,P=0.001),glycosylated hemoglobin level(WMD=-0.59,95%CI:-0.95,-0.24,P=0.001),serum level of total cholesterol(WMD=-20.36,95%CI:-39.80,-0.92,P=0.04),low-density lipoprotein cholesterol(WMD=-20.12,95%CI:-32.95,-7.30,P=0.002)and incidence of myocardial ischemia episodes(SMD=-0.84,95%CI:-1.50,-0.18,P=0.01).However,there were no significant differences in serum triglyceride level,high-density lipoprotein cholesterol,exercise tolerance between the TMZ group and the control group.Conclusion TMZ treatment in diabetic patients with coronary heart disease is effective to improve cardiac function,serum glucose and lipid metabolism and clinical symptoms.

IN PATIENTS WITH HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY AND CORONARY HEART DISEASE,CORONARY FLOW RESERVE IS SIMILARLY IMPAIRED

Coronary blood flow reserve (CFR) was assessed by transesophageal Doppler echocardiography in normal subjects (group A. n=20),hypertensive non-left ventricular hypertrophy (non-LVH)Patients (group B,n=22). hypertensive patients with LVH(group C.n=32)and coronary heart disease patients (group D. n=33) with the volume sample placed at the bifurcation of the left main and left main and left descending coronary artery. Coronary blood flow velocity (CBFV)was evaluated at rest.2 minutes after dipyridamole (0. 56mg/kg. i. v.) . and 2 minutes after aminophylline i.v. The ratio of dipyridamole to rest maximal diastolic velocity (D/R PDV) was considered the index of coronary blood flow reserve.It was found that D/R PDV was significantly less in groups C and D compared with that in groups A and B (D PDC,1.84±0. 57. 1. 57±0. 41 versus 2.59±0.70 and 2.22+0.58,respectively),with no difference in D/R PDV between groups C and D.Twenty-four out of 32 patients in group C with D/R PDV were less than 2.0 compared to 29 out of 33 patients in group D (P>0.05).Significant negative correlation was found between D/R PDV. D/R PSV and interseptal thickness. left ventricular mass index in hypertensive patients.These data show that impaired CFR in hypertensive patients with LVH is comparable to that in patients with coronary heart disease.

Frequency domain cardiography and radionuclide ventriculography for evaluation of left ventricular function in coronary artery disease

Fifty-six patients with chest pain underwent selective coronaryangiography,radionuclide ventriculography (RNV) and frequency domaincardiography (FCG) to evaluate left ventricular function in coronary artery dis-ease (CAD).The sensitivity,specificity and accuracy of FCG were 87.5%,77.8%and 82.9%,respectively,which were slightly less than those of RNV (92.5%,88.9% and 90.8%,respectively).The changes of FCG scores were negatively corre-lated with changes of LVEF (r=-0.586,P【0.01),and TS (r=-0.679,P【0.01).These results indicate that FCG may be useful for the evaluation of leftventricular function in patients with CAD.

Meta-analysis on Efficacy of Yiqi Huoxue Chinese Drugs in the Treatment of Coronary Heart Disease after Coronary Revascularization

[Objectives] To make a systematic evaluation on the therapeutic efficacy and safety of Yiqi Huoxue traditional Chinese drugs combined with western medicine in treatment of coronary heart disease( CHD) after coronary revascularization. [Methods] The literatures were retrieved from China Knowledge Infrastructure( CNKI),Chinese science and technology journal full-text database( VIP database,VIP),Wanfang Data,the Chinese biomedical Database,Pub Med,Embase,and the Cochrane Library. The retrieval time was set to the creation of the database to January 2017. The randomized controlled trial( RCT) was conducted on the comparison between Yiqi Huoxue Chinese drugs combined with western medicine and the western medicine alone in the treatment of CHD after coronary revascularization. The literature information was extracted and the methodological quality of the included literature was evaluated according to the bias risk assessment tool developed by the Cochrane Collaboration. Meta-analysis was performed with the aid of Rev Man 5. 3 software. Coronary artery restenosis rate,angina pectoris treatment efficiency,left ventricular ejection fraction( LVEF),left ventricular end-diastolic volume( LVEDV),B-type natriuretic peptide( BNP),6-minute walk test( 6 MWT),and adverse reactions were analyzed. [Results] A total of 29 articles were included,a total of2 518 patients,the literature quality was low. Meta-analysis results showed that compared with the treatment by western medicine alone,Yiqi Huoxue Chinese drugs combined with western medicine could further reduce coronary restenosis rate[RR = 0. 45,95% CI( 0. 34,0. 60),P <0. 000 01],improve the angina pectoris treatment efficiency[RR = 1. 13,95% CI( 1. 05,1. 21),P = 0. 000 5],raise LVEF[WMD = 4. 25,95% CI( 3. 46,5. 04),P < 0. 000 01],reduce LVEDV[WMD =-10. 41,95% CI(-17. 88,-2. 95),P = 0. 006],decrease the plasma BNP level[WMD =-32. 32,95% CI(-44. 92,-19. 72),P < 0. 000 01],and increase 6 MWT distance(WMD = 62. 25,95% CI( 21. 71,102. 78),P = 0. 003)[Conclusions]Yiqi Huoxue Chinese drugs combined with western medicine can alleviate the symptoms of angina pectoris,reduce the rate of coronary restenosis,improve heart function and improve exercise capacity,thereby improving clinical efficacy in patients with CHD after coronary revascularization.

Correlation between three-dimensional speckle tracking parameters and serum index changes during left ventricular remodeling in patients with coronary heart disease

Objective:To study the correlation between three-dimensional speckle tracking parameters and serum index changes during left ventricular remodeling in patients with coronary heart disease. Methods: Patients who were diagnosed with coronary heart disease and angina pectoris in our hospital between March 2015 and May 2017 were selected as the CHD group of the study, and the healthy subjects who received medical examination in our hospital during the same period were taken as the control group;the three-dimensional speckle tracking parameters, peripheral blood signal molecule expression as well as serum cytokine and collagen metabolism index levels of the two groups were measured.Results: GLS and AGS levels in CHD group were significantly lower than those in control group whereas GCS and GRS levels were not significantly different from those in control group, and peripheral blood Notch1, Hes1, NF-κB and PKC expression intensity as well as serum sTWEAK, FGF23, TGF-β1, GDF15, sSema4D, CaN, MMP14, PINP and ICTP contents were significantly higher than those of control group;GLS and AGS levels in CHD group were negatively correlated with peripheral blood Notch1, Hes1, NF-κB and PKC expression intensity as well as serum sTWEAK, FGF23, TGF-β1, GDF15, sSema4D, CaN, MMP14, PINP and ICTP contents.Conclusions:The changes of three-dimensional speckle tracking parameters GLS and AGS in patients with coronary heart disease are closely related to the changes in signal pathway function, cytokine secretion and collagen metabolism during left ventricular remodeling.

Effect of Different Styles of Coronary Heart Disease and Its Risk Factors on Cardiac Remodeling and Dysfunction

Objectives To evaluate the effect of different styles of coronary heart disease （CHD）, different regions of acute myocardial infarction （AMI）, its risk factors and branches of coronary stenosis on left ventricular remodeling and dysfunction by applying echocardiography. Methods 251 patients with CHD and 96 patients without CHD （NoCHD） were verified by selective coronary angiography. CHD patients were divided into stable angina pectoris （SAP） 26, unstable angina pectoris（UAP） 53, acute myocardial infarction （AMI） 140 and old myocardial infarction （OMI） 30 based on clinical situation, cTnT, cardiac enzyme and ECG. AMI patients were further divided into subgroups including acute anterior myocardial infarct （Aa,n = 53）, acute inferior myocardial infarction （Ai, n=54） and Aa＋Ai （n=33） based on ECG. Cardiac parameters： end-diastolic interventricular septum thickness（IVSd）, end-diastolic left ventricular internal diameter （LVd）, left ventricular mass （LM）, end-diastolic left ventricular volume （EDV）, end-systolic left ventricular volume （ESV） and left ventricular ejection fraction（LVEF） were measured by ACUSON 128XP/10 echocardiography. Multiples linear regression analyses were performed to test statistical associations between LVEF and the involved branches of coronary stenosis, blood pressure, lipids, glucose and etc after onset of myocardial infarction. Results EDV and ESV were increased and LVEF decreased on patients with AMI,OMI and UAP （P〈0.05-0.0001）. LM was mainly increased in patients with OMI （P〈0.01） and LVd was mainly enlarged in patients with AMI. EF was significantly decreased and EDV, ESV, LM and LVd were remarkably increased in AMI patients with Aa and Aa＋Ai. With the multiple linear regression analyses by SPSS software, we found that LVEF was negatively correlated to the involved branches of coronary stenosis as well as to systolic blood pressure after onset of myocardial infarction while there was no significant correlation between LVEF and other factors. LVEF was significantly decreased, and LVd and LM increased in AMI patients with antecedent hypertension, compared to patients without hypertension （P〈0.001）. Conclusions Effects of different styles of CHD and different regions of AMI on left ventricular remodeling and cardiac function are different. Myocardial infarction, especially Aa and Aa＋Ai, is one of the most important causes of left ventricular remodeling and cardiac dysfunction. Multiple vessel stenosis and systolic blood pressure at the onset of myocardial infarction reduce LVEF in AMI patients. Antecedent hypertension may accelerate the effect of AMI on cardiac remodeling and dysfunction. Therefore primary and secondary preventions of CHD are critical for protecting heart from remodeling and dysfunction.

Low doses of intravenous epinephrine for refractory sustained monomorphic ventricular tachycardia

We report three cases of sustained monomorphic ventricular tachycardia(VT) in the setting of coronary artery disease,resistant to beta-blockers in two patients and to amiodarone in all,successfully terminated by low doses of intravenous(IV) epinephrine.VT was the first manifestation of coronary artery disease in one patient,whereas the other two patients had a previous history of myocardial infarction and were recipients of an implantable cardioverter-defibrillator(ICD).One of these two patients experienced an arrhythmic storm.All had hemodynamic instability at the time of epinephrine administration.A single slow administration of IV epinephrine(0.5 to 1 mg administered over 30 to 60 s) restored sinus rhythm after 30-90 s with only minor side effects.In the ICD patient with recurrent VT and several cardioversions due to transformation of VT to ventricular fibrillation,epinephrine injection led to the avoidance of further shocks.Although potentially harmful,low doses of IV epinephrine used alone or in combination with beta-blocker treatment and electrical cardioversion may be an alternative effective therapy for sustained monomorphic VT refractory to amiodarone.The role of epinephrine in the termination of VT should be studied further,especially in patients pre-treated with amiodarone in combination with beta-blockers.

Coronary Artery Complications after Right Ventricular Outflow Tract Reconstruction Surgery

Background:Mechanisms and clinical manifestations of coronary artery complications after right ventricular outflow tract reconstruction surgery are not well known.Methods:Patients who had coronary artery complications after pulmonary valve replacement or the Rastelli procedure at a single tertiary centre were retrospectively analysed.Results:Coronary artery complications were identified in 20 patients who underwent right ventricular outflow tract reconstruction surgery.The median age at diagnosis of coronary artery complication was 21 years(interquartile range:13–25 years).Mechanisms of coronary artery complications were compression by adjacent materials in 12 patients,dynamic compression of intramural course of coronary artery in two patients,and intraoperative injury in six patients.Congenital coronary artery anomalies were identified in 50%(10/20)of patients.Four patients presented with early postoperative haemodynamic instability.Fourteen patients showed late onset symptoms or signs of coronary insufficiency,including chest pain,ventricular dysfunction,or ventricular arrhythmias.Coronary artery stenosis was incidentally found on cardiac computed tomography angiography in two asymptomatic patients.Four patients underwent surgical interventions,and one patient underwent percutaneous coronary intervention for coronary stenosis.One patient with recurrent ventricular tachycardia required an implantable cardioverter-defibrillator.There were two deaths in patients with intraoperative coronary injury.Conclusion:Preoperative coronary evaluation and long-term follow-up for the development of coronary artery complications are required in patients undergoing right ventricular outflow tract reconstruction surgery to prevent ventricular dysfunction,arrhythmias,and death,especially among those with congenital coronary anomalies.

冠状动脉CT血管造影预测冠心病患者发生左心室重构及远期心血管不良事件的价值

目的分析冠状动脉CT血管造影预测冠心病患者发生左心室重构及远期心血管不良事件的价值。方法选取郑州大学第一附属医院2021年1月至2022年7月诊治的120例冠心病患者,随访1 a,根据左心室重构发生情况分为左心室重构组(26例)、无左心室重构组(94例),根据心血管不良事件发生情况分为发生组(24例)、未发生组(96例)。比较不同组别患者冠状动脉CT血管造影结果,分析冠状动脉CT血管造影预测冠心病患者发生左心室重构及远期心血管不良事件的价值。结果左心室重构组、无左心室重构组在冠状动脉管腔狭窄程度和高危斑块特征方面的差异有统计学意义(P<0.05)。发生组、未发生组斑块总体积、钙化斑块体积、非钙化斑块体积、病变长度、斑块负荷比较,差异有统计学意义(P<0.05)。受试者工作特征(ROC)曲线分析显示,冠状动脉CT血管造影在预测冠心病患者发生左心室重构及远期心血管不良事件中具有较高的价值。结论冠状动脉CT血管造影在预测冠心病患者发生左心室重构及远期心血管不良事件中具有较高的价值。

参松养心胶囊治疗老年冠心病室性早搏气阴两虚、心络瘀阻型患者临床观察

目的:观察参松养心胶囊对老年冠心病室性早搏气阴两虚、心络瘀阻型患者临床疗效、动态心电图室性早搏次数及中医证候积分的影响。方法:选择老年冠心病室性早搏气阴两虚、心络瘀阻型患者60例,按照随机数字表法分为对照组和观察组,每组30例。对照组给予口服酒石酸美托洛尔,观察组在对照组基础上口服参松养心胶囊。两组均连续治疗4周。观察两组治疗前后临床疗效,24 h动态心电图室性早搏次数及中医证候积分。结果:对照组有效率[73.33%(22/30)]高于观察组[96.67%(29/30)](P<0.05)。两组治疗后室性早搏次数均减少,观察组减少较对照组更明显(P<0.05)。与治疗前比较,两组心悸、悸动不安、神疲乏力、气短、五心烦热等中医证候积分均下降(P<0.05),且治疗后观察组上述指标改善优于对照组(P<0.05)。结论:参松养心胶囊能有效减少老年冠心病室性早搏患者的室性早搏次数,改善患者临床症状。

阿司匹林联合替格瑞洛治疗冠心病不稳定型心绞痛的疗效及对患者心室重塑、氧化应激的影响

目的 观察阿司匹林联合替格瑞洛治疗冠心病不稳定心绞痛的疗效,并评估其对患者心室重塑、氧化应激等指标的影响。方法 选取2021年10月至2023年10月期间新乡市中心医院收治的186例冠心病不稳定心绞痛患者纳入研究,采用随机数表法分为观察组和对照组,每组93例。对照组患者采用阿司匹林联合氢氯吡格雷片治疗,观察组患者采用阿司匹林联合替格瑞洛治疗,均连续治疗3个月。比较两组患者的临床疗效,以及治疗前后的心室重塑[基质金属蛋白酶-9 (MMP-9)、半乳凝素-3 (Gal-3)]、血管内皮功能[血清细胞间黏附分子-1 (ICAM-1)、血管紧张素Ⅱ(AngⅡ)、内皮素-1 (ET-1)、血流介导舒张功能(FMD)水平]和氧化应激[一氧化氮(NO)、丙二醛(MDA)、超氧化物歧化酶(SOD)]水平。结果 观察组患者的治疗总有效率为96.77%,明显高于对照组的86.02%,差异有统计学意义(P<0.05);观察组患者治疗后的MMP-9水平为(141.28±19.33)μg/L,明显低于对照组的(164.72±19.86)μg/L,而Gal-3水平为(6.87±0.92) ng/mL,明显高于对照组的(5.36±0.84) ng/mL,差异均有统计学意义(P<0.05);观察组患者治疗后的ICAM-1、AngⅡ和ET-1水平分别为(56.87±9.70) pg/mL、(0.70±0.14) ng/mL和(43.15±5.83) pg/mL,明显低于对照组的(81.35±10.31) pg/mL、(0.96±0.15) ng/mL和(52.37±6.37) pg/mL,而FMD水平为(14.82±1.93)%,明显高于对照组的(11.27±2.33)%,差异均有统计学意义(P<0.05);观察组患者治疗后的NO、SOD水平分别为(77.95±9.60) mol/L、(112.69±11.47) U/L,明显高于对照组的(62.49±9.37) mol/L、(107.34±10.63) U/L,而MDA水平为(12.45±2.26) mmol/L,明显低于对照组的(15.38±2.35) mmol/L,差异均有统计学意义(P<0.05)。结论 阿司匹林联合替格瑞洛治疗不稳定型冠心病疗效确切,且能促进患者的心室重塑、改善血管内皮功能及氧化应激指标。

无节段性室壁运动异常冠心病患者PCI术后左室功能的效果评价

目的应用常规超声心动图及三维应变定量评价无节段性室壁运动异常冠心病患者经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗前后左室收缩和舒张功能的变化,探讨PCI手术及支架置入数目对冠心病患者的疗效。方法选择112例无节段性室壁运动异常的冠心病患者,分别于PCI术前3 d及术后6个月行超声心动图检查,根据支架置入数目分三组,即1枚支架组(n=55)、2枚支架组(n=35)和3枚支架组(n=22),收集其基本临床资料、常规超声心动图数据及三维应变数据,并计算出相应方向的应变显像舒张功能指数(SI-DI)分析其变化。结果PCI术前术后两组数据比较,PCI术前pro-BNP数值高于术后值(P<0.05),收缩压、舒张压、血糖、血脂、体质量指数(BMI)等项目术前术后数据差异无统计学意义。PCI术前术后两组常规超声参数比较,两组间E、e′、EDV、ESV、及E/e′术后较术前升高,两组间LVEF、SV比较,术后较术前降低,但其差异均无统计学意义。PCI术前术后两组三维参数比较,PCI术前术后两组GLS、GRS、GAS、GCS、L-SI-DI、A-SI-DI、C-SI-DI、RSI-DI差异有统计学意义(均P<0.01),PCI术后明显高于术前。不同支架数3组间三维参数比较,PCI术前三组各方向应变及相应SI-DI差异无统计学意义。PCI术后随着支架数目的增加,GLS、GAS、GCS、GRS、L-SI-DI、ASI-DI、C-SI-DI及R-SI-DI呈减低趋势。2枚支架组GCS、L-SI-DI均低于1枚支架组(均P<0.05),3枚支架组GLS、GCS、GAS、L-SI-DI、C-SI-DI、A-SI-DI均低于1枚支架组(均P<0.05),3枚支架组GLS、GCS、GAS、L-SIDI、C-SI-DI低于2枚支架组(均P<0.05);三组间GRS和R-SI-DI差异无统计学意义。不同数目支架组各参数术后较术前呈升高趋势,1枚支架组GLS、GAS、GCS、GRS、L-SI-DI、A-SI-DI、C-SI-DI高于术前(均P<0.05),2枚支架组GAS高于术前(P<0.05),3枚支架组手术前后差异无统计学意义。结论三维应变优于常规超声心动图,可以定量评价PCI术后左室收缩和舒张功能改变,评估冠心病患者PCI治疗效果;支架置入数目与PCI术后左室功能恢复情况有关。

益气养心方治疗冠心病室性心律失常的疗效及其对心肌缺血的血液流变学指标、CXCL9水平的影响

目的观察益气养心方治疗冠心病室性心律失常的临床疗效及其对心肌缺血的血液流变学指标、CXC趋化因子配体9(CXCL9)水平的影响。方法选取2021年6月至2022年12月在该院治疗的70例冠心病室性心律失常患者作为研究对象,采用随机数字表法分为对照组和观察组,每组35例。两组患者均实施常规对症治疗,对照组在常规对症治疗的基础上给予酒石酸美托洛尔片治疗,观察组在对照组的基础上给予益气养心方治疗,两组患者均连续治疗4个月。观察两组临床疗效、血液流变学指标水平、血清CXCL9水平及不良反应情况。结果观察组治疗后总有效率高于对照组(P<0.05);两组治疗后全血低切黏度、全血高切黏度、血浆比黏度、纤维蛋白水平均低于治疗前,且观察组均低于对照组(P<0.05);两组治疗后血清CXCL9水平均低于治疗前,且观察组低于对照组(P<0.05);两组治疗过程中均未见严重不良反应,仅有极少数患者出现轻微恶心、呕吐症状。结论益气养心方治疗冠心病室性心律失常临床疗效较佳,可调低血清CXCL9水平,减轻心肌损伤,改善心肌的血液流变学指标,促进心律失常改善,且治疗安全性较高。

药物涂层球囊与药物洗脱支架在冠心病患者行冠状动脉介入治疗中的应用价值比较

目的对比药物涂层球囊与药物洗脱支架对行冠状动脉介入治疗(PCI)的冠心病患者的影响.方法选取2021年1月—2022年12月该院收治的150例行PCI治疗的冠心病患者为研究对象,按随机数字表法将其分为对照组与观察组,各75例.对照组行药物洗脱支架,观察组行药物涂层球囊.对比两组患者的再狭窄发生率、心功能、主要心血管不良事件(MACE)发生率.结果观察组再狭窄发生率为4.00%,MACE发生率为2.67%,均低于对照组的13.89%、12.00%,组间差异有统计学意义(P<0.05).术后1年,观察组左室收缩末期内径为(38.71±2.83)mm,左室舒张末期内径为(42.46±3.74)mm,均短于对照组的(45.89±3.26)mm、(49.71±4.26)mm,左室射血分数为(59.53±5.29)%,高于对照组的(53.48±4.76)%,每搏输出量为(70.31±6.18)mL,多于对照组的(64.25±5.29)mL,组间差异有统计学意义(P<0.05).结论药物涂层球囊更能够改善行PCI的冠心病患者心功能,降低再狭窄率与MACE发生率,有一定的应用价值,值得临床进行推广应用.

炙甘草汤联合西药治疗气阴两虚型冠心病合并室性心律失常患者的效果

目的探讨炙甘草汤联合西药治疗气阴两虚型冠心病合并室性心律失常(VA)的临床效果。方法选取济南市第三人民医院2022年1月—2023年10月收治的56例冠心病合并VA患者为研究对象,按随机数字表法将其分为对照组和观察组,每组28例。对照组采用西药治疗,观察组在此基础上采用炙甘草汤治疗,均持续6周。比较两组患者的临床疗效、心电图指标、中医证候积分及不良反应发生情况。结果观察组的治疗总有效率为92.86%,高于对照组的71.43%,差异有统计学意义(P<0.05)。治疗6周后,观察组的室性期前收缩数、短阵室速数分别为(2824.63±225.31)次/24 h、(1.82±0.23)次/24 h,均少于对照组的(3025.59±234.16)次/24 h、(2.89±0.35)次/24 h,QT间期为(458.63±45.32)ms,长于对照组的(419.63±44.25)ms,QT离散度为(37.12±3.25)ms,短于对照组的(42.65±4.18)ms,组间差异有统计学意义(P<0.05);观察组的心悸胸闷、气短乏力、头晕眼花、失眠健忘积分分别为(0.76±0.13)分、(0.65±0.11)分、(0.59±0.11)分、(0.62±0.13)分,均低于对照组的(0.89±0.15)分、(0.84±0.13)分、(0.78±0.13)分、(0.81±0.14)分,组间差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论炙甘草汤联合西药可提高冠心病合并VA患者的治疗效果,改善其心电图指标,降低中医证候积分,且安全性良好。

美托洛尔联合瑞舒伐他汀治疗老年冠心病并室性心律失常临床研究

目的探讨美托洛尔联合瑞舒伐他汀治疗老年冠状动脉粥样硬化性心脏病(简称冠心病)并室性心律失常的临床疗效。方法选取医院2020年1月至2023年2月收治的冠心病并室性心律失常老年患者98例,按随机数字表法分为观察组和对照组,各49例。两组患者均予利尿剂、血管扩张剂、抗血小板聚集药物等基础治疗,并口服瑞舒伐他汀钙片,观察组患者加服琥珀酸美托洛尔缓释片。两组患者均连续治疗3个月。结果观察组总有效率为95.92%,显著高于对照组的81.63%(P<0.05)。与治疗前比较,两组患者治疗后的室性期前收缩、成对室性期前收缩、短期阵发室性心动过速发作次数24 h内均显著减少,左心室射血分数显著升高,左心室舒张末期内径、左心室收缩末期内径均显著缩短(P<0.05);血管内皮生长因子、一氧化氮水平均显著升高,内皮素-1、可溶性生长刺激表达基因2蛋白、心肌肌钙蛋白I、N末端脑钠肽前体水平均显著降低(P<0.05);肿瘤坏死因子-α、髓过氧化物酶、超敏C反应蛋白、低密度脂蛋白胆固醇、甘油三酯、总胆固醇水平均显著降低,高密度脂蛋白胆固醇水平均显著升高(P<0.05);三水平五维健康量表中视觉模拟量表评分显著升高(P<0.05)。观察组以上指标改善幅度均显著大于对照组(P<0.05)。观察组与对照组不良反应发生率相当(12.24%比10.20%,P>0.05)。结论美托洛尔联合瑞舒伐他汀治疗老年冠心病并室性心律失常,能减少室性心律失常的发作次数,改善心功能、血管内皮功能及血脂水平,抑制心肌损伤及炎性反应,提高患者的生活质量。